A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
Conditions: Advanced Solid Tumor (Phase 1); Pancreas Adenocarcinoma; Non-small Cell Lung Cancer; Malignant Melanoma (Cutaneous) Interventions: Drug: IMM-6-415 Sponsors: Immuneering Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2024 Category: Research Source Type: clinical trials
Quantitative Analysis of PET/CT Images of Immune Related Side Effects in Metastatic Melanoma Patients
Conditions: Melanoma; PET CT Interventions: Diagnostic Test: additional PET/CT at 4 weeks, analysing using quantative analysis Sponsors: Institute of Oncology Ljubljana Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2024 Category: Research Source Type: clinical trials
AMT-253 in Patients With Advanced Solid Tumours
Conditions: Malignant Melanoma; Advanced Solid Tumors Interventions: Drug: AMT-253 for injection Sponsors: Multitude Therapeutics Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2024 Category: Research Source Type: clinical trials
A Phase 1/2a Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
Conditions: Advanced Solid Tumor (Phase 1); Pancreas Adenocarcinoma; Non-small Cell Lung Cancer; Malignant Melanoma (Cutaneous) Interventions: Drug: IMM-6-415 Sponsors: Immuneering Corporation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 17, 2024 Category: Research Source Type: clinical trials
FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis
Conditions: Diarrhea; Colitis; Malignant Melanoma; Kidney Cancer Interventions: Procedure: Faecal Microbiota Transplantation (FMT); Procedure: Placebo Sponsors: University of Aarhus Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 15, 2024 Category: Research Source Type: clinical trials
To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma
Conditions: Melanoma Stage III; Melanoma Stage IV; Melanoma Interventions: Biological: ADP-TILIL7; Drug: Cyclophosphamide; Drug: Fludarabine Phosphate; Drug: Proleukin Sponsors: Inge Marie Svane; Adaptimmune Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 12, 2024 Category: Research Source Type: clinical trials
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients
Conditions: Melanoma; Melanoma Stage III; Melanoma Stage IV; Unresectable Melanoma Interventions: Diagnostic Test: 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Sponsors: University of Wisconsin, Madison Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 10, 2024 Category: Research Source Type: clinical trials
Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
Conditions: Melanoma Interventions: Drug: Defactinib; Drug: Avutometinib; Drug: Encorafenib Sponsors: University of Utah; Verastem, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 8, 2024 Category: Research Source Type: clinical trials
Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma
Conditions: Stage IIIB Melanoma; Stage IIIC Melanoma; Stage IIID Melanoma Interventions: Biological: LN-144; Drug: Cyclophosphamide; Drug: Mesna; Drug: Fludarabine; Biological: Interleukin-2 (IL-2); Drug: Pembrolizumab Sponsors: James Isaacs, MD Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
A Trial to Learn if Fianlimab and Cemiplimab Are Safe and Work Better Than Pembrolizumab in Adult Participants With Resectable Stage 3 or 4 Melanoma
Conditions: Melanoma Interventions: Drug: pembrolizumab; Drug: fianlimab HD; Drug: cemiplimab; Drug: fianlimab LD; Drug: Placebo Sponsors: Regeneron Pharmaceuticals Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2024 Category: Research Source Type: clinical trials
Holistic Needs Assessments in Patients With Melanoma
Conditions: Melanoma; Unsatisfied Needs Interventions: Other: Holistic needs assessment based on the use of patient-reported outcome measures Sponsors: University of Surrey Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 3, 2024 Category: Research Source Type: clinical trials
Managing Distress in Malignant Brain Cancer - Ph II Randomized Crontrolled Trial
Conditions: Brain Tumor; Brain Metastases; Brain Cancer; Metastatic Lung Cancer; Metastatic Breast Cancer; Metastatic Melanoma; Metastatic Colon Cancer; Metastatic Kidney Cancer Interventions: Behavioral: CALM; Behavioral: Treatment as usual Sponsors: Virginia Commonwealth University; United States Department of Defense Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 22, 2023 Category: Research Source Type: clinical trials
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Conditions: Advanced Solid Tumor; Melanoma; Head and Neck Cancer; Gastric Cancer Interventions: Drug: HER3-DXd Sponsors: Daiichi Sankyo, Inc.; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 15, 2023 Category: Research Source Type: clinical trials
Moderna and Merck Announce mRNA-4157 (V940) in Combination with Keytruda ® (pembrolizumab) Demonstrated Continued Improvement in Recurrence-Free Survival and Distant Metastasis-Free Survival in Patients with High-Risk Stage III/IV Melanoma Following Complete Resection Versus KEYTRUDA At Three Years
At a median planned follow-up of approximately three years, mRNA-4157 (V940) in combination with KEYTRUDA reduced the risk of recurrence or death by 49% (HR=0.510 [95% CI, 0.288-0.906]; one-sided nominal p=0.0095) and the risk of distant... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - December 14, 2023 Category: Pharmaceuticals Source Type: clinical trials
Mind Over Matter for Black and African American Women: A Single Arm Trial Examining Feasibility and Acceptability of a Supportive Intervention
Conditions: Cancer; Breast Cancer; Brain Cancer; Central Nervous System Cancer; Colorectal Cancer; Esophageal Cancer; Gynecologic Cancer; Head and Neck Cancer; Gastrointestinal Cancer; Genitourinary Cancer; Melanoma; Blood Cancer; Lung Cancer; Acceptance and Commitment Therapy; Mind-Body Therapies; Psychosocial Intervention Interventions: Other: Mind Over Matter (MOM) Sponsors: Inova Health Care Services; Howard University; University of Louisville; University of Houston; Massey Cancer Center; Tigerlily Foundation Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 13, 2023 Category: Research Source Type: clinical trials
